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Identity 
Other names: HNP, NP, NRPN, PRSS19, TADG14 
HGNC (Hugo): KLK8  
Location: 19q13.41 
Local order: Telomere to centromere. 
Note 
This gene is one of the fifteen kallikrein subfamily  
members located in a cluster on chromosome 19. 
Kallikreins are a subgroup of serine proteases having 
diverse physiological functions. 
DNA/RNA 
Description 
The KLK8 gene is approximately 7.8 kb in length, 
consisting of 8 exons (5 of them are coding exons) a d 
7 introns. 
Transcription 
Human KLK8 was originally cloned (Yoshida et al., 
1998) as the human ortholog of the mouse brain 
protease neuropsin (Chen et al., 1995). Using Northern 
blot and RT-PCR analyses, it has been shown that 
KLK8 is expressed mainly in breast, cervix, esophagus, 
skin, ovary, testis, salivary glands and vagina. Adrenal, 
brain, colon, heart, kidney, lung, muscle and prostate 
also express KLK8 mRNA at medium to low levels. 
The transcription start site of KLK8 appears tissue-
specific (Lu et al., 2009). Eight alternatively spliced 
variants have been identified for the KLK8 gene. These 
variants differ in the number and length of the 5' 
untranslated exons and/or coding exons. The splice 
variants are predicted to encode 6 protein isoforms.  
Type 1 and Type 2 transcripts differ in their coding 
exon 2 sequence. Type 2 includes extra 45 amino acids 
at the N-terminus of the coding exon 2. 
Thus, Type 1 and Type 2 KLK8 mRNA variants 
produce 2 zymogens that differ only in their propeptide 
sequences. Type 2 variant is absent in nonhuman 
primates, and is thus a human-specific splice form (Li 
et al., 2004; Lu et al., 2007). Type 1 mRNA is 
predominantly expressed in the pancreas and Type 2 
mRNA in adult brain and hippocampus. Type 2 KLK8 
is also abundantly expressed in fetal brain, placenta a d 
in human embryonic stem cells, suggesting a potential 
role in embryogenesis (Mitsui et al., 1999; Lu et al.,
2009).  
The Type 3 mRNA variant includes coding exons 1, 4, 
and 5 and encodes a truncated form of the KLK8 
protein (Magklara et al., 2001). Type 4 variant lacks 
coding exons 2, 3, 4.  
It encodes a putative protein of 32 amino acid residues 
that contains the KLK8 signal peptide and another 
peptide that is not related to KLK8 (Magklara et al., 
2001).  
Type 3 and Type 4 mRNAs are abundant in many 
normal tissues (brain, pancreas, skin) and are 
overproduced in ovarian and lung cancers (Magklara et 
al., 2001; Planque et al., 2010). Coding exon 2 is 
missing in Type 5 mRNA whereas Type 6 mRNA lacks 
coding exon 3. For these both variants, the alternaive 
splicing creates a stop codon that prematurely 
terminates translation. Type 5 and Type 6 mRNAs 
were detected in lung cancer cell lines and tissues (Sher 
et al., 2006; Planque et al., 2010). 
Pseudogene 
None identified. 
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The KLK8 gene comprises 8 exons (dark color, classic numerals) and 7 introns. Shown here are the 6 alternative transcripts predicted to 
encode protein variants (only the coding exons are depicted). Yellow boxes: non coding sequences; blue and green boxes: coding 





The canonical KLK8 protein encoded by Type 1 
mRNA has a secretion signal (pre-) peptide (28 amino 
acids), followed by an activation (pro-) peptide (4 
amino acids) and the mature chain (228 amino acids) 
with 1 potential N-linked glycosylation site. The 
catalytic triad of His73, Asp120, Ser212 (relative to 
Met = 1) is conserved and is essential for proteolytic 
activity. After synthesis as a KLK8 precursor, the 
signal peptide is then cleaved and pro-KLK8 
(zymogen) is subsequently secreted from the cell. Upon 
activation, the propeptide is removed to generate the 
mature active enzyme. Type 2 KLK8 has an insert of 
45 amino acids between Ala23 and Gly24 at the C-
terminus of the leader sequence of canonical KLK8. 
Therefore, this isoform has larger signal peptide and
propeptide and has been produced intact as 
recombinant protein (Lu et al., 2009). Beside the 
canonical KLK8 protein, only the predicted peptide 
encoded by KLK8 Type 4 mRNA has been yet detected 
in vivo. This form was identified by mass spectrometry 
in bronchoalveolar lavage fluid (Oumeraci et al., 2011). 
Expression 
KLK8 protein has been detected in a wide range of 
tissues at low (10 to 100 ng/g, adrenal, cervix,  
heart, kidney, liver, ovary, salivary gland, vagina) to 
high (1 µg to 10 µg/g, breast, esophagus, skin, tensil) 
levels (Shaw and Diamandis, 2007).  
KLK8 has also been detected in body fluid, such as 
milk, amniotic fluid, cerebrospinal fluid, seminal 
plasma, serum, saliva and sweat (Kishi et al., 2003; 
Shaw and Diamandis, 2007; Eissa et al., 2011).  
Age at the first full term pregnancy (FFTP) influenc s 
secretion of KLK8 protein in breast milk. Indeed in a 
recent study, a significant increase in KLK8 expression 
was observed from the onset of lactation to breast 
weaning depending on FFTP age (26) (Qin et al., 
2012). 
Localisation 
KLK8 is a secreted protein and is localized 
intracellularly to the cytoplasm.  
In epidermis, KLK8 is localized within the trans-Golgi 
network, lamellar granules and intercellular spaces 
between the stratum granulosum and stratum corneum 
(Ishida-Yamamoto et al., 2004).  
Diffuse cytoplasmic staining was observed for KLK8 
in the secretory segment in eccrine sweat glands an in 
the intradermal sensory nerve (Komatsu et al., 2005).  
KLK8 is present in relatively high levels in ductal cells, 
as well as in non-ductal cells, of normal salivary gland 
tissues and benign and malignant salivary gland tumors 
(Darling et al., 2008).  
In brain, KLK8 is expressed in the cell body of 
oligodendrocytes (He et al., 2001). 
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Schematic structure of the KLK8 Type1 protein. The amino acid numbering for the residues of the catalytic triad (His70, Asp120, Ser212) 
are relative to the full-length protein starting from Met1. 
 
Function 
KLK8 is a serine protease which exhibits trypsin-like 
activity with strong preference for Arg over Lys in the 
P1 position (Kishi et al., 2006; Eissa et al., 2011). 
KLK8 activity is inhibited by general serine proteas  
inhibitors such as a2-antiplasmin, protein C inhibitor 
and PI-6 (Proteinase inhibitor 6) (Scott et al., 2007). 
Several potential substrates have been identified for 
KLK8 in human or mouse including extracellular 
matrix components (Single-chain tPA, fibronectin, 
gelatin, collagen type IV, fibrinogen) (Rajapakse et al., 
2005), cell adhesion molecules (L1cam) and 
membranous receptors (EphB2, PAR2) (Matsumoto-
Miyai et al., 2003; Nakamura et al., 2006; Attwood et 
al., 2011; Ramachandran et al., 2012), antimicrobial 
peptides (LL-37) and zymogens of kallikrein-related 
peptidases (proKLK1 and proKLK11) (Eissa et al., 
2011). The physiological functions of KLK8 are not 
fully understood. Accumulating evidence has suggested 
pivotal roles for KLK8 in development, maturation ad 
cognitive functions. KLK8 induces neurite outgrowth 
and fasciculation of cultured hippocampal neurons. 
Plays a role in the formation and maturation of orphan 
and small synaptic boutons in the Schaffer-collateral 
pathway, regulates Schaffer-collateral long-term 
potentiation in the hippocampus and is required for 
memory acquisition and synaptic plasticity (Komai et 
al., 2000; Oka et al., 2002; Nakamura et al., 2006; 
Terayama et al., 2007; Horii et al., 2008; Yoshida, 
2010; Ishikawa et al., 2011; Shiosaka and Ishikawa, 
2011). KLK8 has also been involved in skin 
desquamation and wound healing and in keratinocyte 
proliferation (Inoue et al., 1998; Kirihara et al., 2003; 
Kishibe et al., 2007; Yoshida, 2010; Eissa et al., 2011; 
Kishibe et al., 2012). It has been shown that KLK8 is 
differentially expressed in a number of malignancies, 
including ovarian, cervical, head and neck, breast and
salivary gland cancers (Kishi et al., 2003; Cane et al., 
2004; Borgono et al., 2006; Darling et al., 2008; Liu et 
al., 2008; Kountourakis et al., 2009), but the 
mechanisms of its involvement in these cancer have yet 
to be determined. In lung cancer, KLK8 suppress tumor 
cell invasiveness in vitro and in vivo (Sher et al., 2006). 
Homology 
The human KLK8 protein sequence shares 40-70% 
homology with other members of the human tissue 




Genomewide DNA linkage analysis identified a 
susceptibility locus for intracranial aneurysm (IA) on 
chromosome 19q13 in the Finnish population. Two 
SNPs located in the intronic region of KLK8 were 
found significantly associated with IA (Weinsheimer et 
al., 2007). A significant allelic association between 
several KLK8 SNPs and bipolar disorder has recently 
been reported (Izumi et al., 2008).  
No germinal or somatic mutations are identified to be 




Several carcinomas (ovarian, cervical, oral, salivary 
glands and lung cancers) show high expression of the 
KLK8 gene. Depending on the cancer type, KLK8 acts 
as tumor promoting or tumor suppressing factor. 
Ovarian cancer 
Disease 
Expression of KLK8 was not detected on the surface 
epithelium of normal ovaries by 
immunohistochemistry. In contrast, KLK8 protein was 
detected in ovarian carcinomas with a significantly 
higher detection rate of KLK8 expression in early stage 
disease compared to advanced stage disease 
(Shigemasa et al., 2004). Other analyses using 
sandwich-type immunoassays found KLK8 protein in 
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cancer tissue extracts, serum and ascites fluid of 
ovarian cancer patients (Kishi et al., 2003; Shigemasa 
et al., 2004; Borgono et al., 2006). 
Prognosis 
It had been proposed that KLK8 is an independent 
marker of favorable prognosis in ovarian cancer at both 
the mRNA and protein levels. For example, KLK8 
mRNA levels were found associated with longer 
disease-free survival (PFS) (Magklara et al., 2001; 
Shigemasa et al., 2004). The tissue concentration of 
KLK8 was also described as an independent marker of 
favorable prognosis in ovarian cancer. Patients with 
KLK8-positive tumors had a significantly longer PFS 
and overall survival than KLK8-negative patients 
(Borgono et al., 2006). Higher ascites fluid KLK8 
concentration was also associated with better ovarian 
cancer PFS (Kishi et al., 2003). Using another 
approach, Kountourakis et al. showed significant 
correlations between tumour mask KLK8 protein 
expression levels and clinicopathological variables, 
including grade, residual disease and clinical respon e 
to chemotherapy. There was also a significant 
correlation between KLK8 tumour mask expression 
and five years progression-free survival (Kountourakis 
et al., 2009). 
Non-small cell lung cancer 
Disease 
In non-small cell lung cancer (NSCLC), KLK8 appears 
to suppress tumor cell invasiveness by degrading 
fibronectin, thereby suppressing integrin signaling, and 
also retards cancer cell motility by inhibiting actin 
polymerization. In a mouse model, KLK8 suppresses 
tumor growth and invasion in vivo (Sher et al., 2006). 
Compared with sera from normal subjects, sera of 
patients with NSCLC had lower levels of KLK8. Using 
a KLK8 ELISA on 51 patients with NSCLC and 50 
normal controls, it was shown that KLK8 may have 
utility as a lung cancer biomarker when used in 
conjunction with KLK4, KLK10, KLK11, KLK12, 
KLK13, and KLK14 (Planque et al., 2008). 
Prognosis 
In patients with non-small cell lung cancer, the time to 
postoperative recurrence was longer for early-stage 
patients with high KLK8 gene expression than for 
patients with low KLK8 gene expression (Sher et al., 
2006). Another study has revealed that the Type 4 
KLK8 alternative splice variant, alone or in 
combination with other KLK mRNAs, may be a new 
independent marker of unfavorable prognosis in lung 
cancer (Planque et al., 2010). 
Breast cancer 
Disease 
KLK8 is downregulated in breast cancer tissues and 
cell lines (Yousef et al., 2004). On the other hand, 
KLK8, along with several other kallikrein genes, could 
be primarily up-regulated by 17b-estradiol and, to a 
lesser degree, by other steroid hormones in hormone 
receptor-positive breast cancer cell lines MCF-7 and T-
47D, suggesting a coordinated kallikrein expression as 
part of a complex regulatory mechanism that controls 
the expression of these genes and also their 




At the mRNA level, KLK8 was found to be highly 
expressed in 82% primary cervical cancer cell lines and 
in 87% established cervical cancer cell lines. In 
addition, immunohistochemistry staining of paraffin-
embedded cervical cancer specimens showed KLK8 
expression in tumor cells and its absence on normal 
cervical epithelial cells (Cane et al., 2004). 
Bladder cancer 
Disease 
Reverse transcription-polymerase chain reaction 
analysis of 42 primary bladder tumor samples revealed 
an higher expression level of KLK8 mRNA in invasive 
tumors than in superficial tumors (Shinoda et al., 
2007). 
Salivary gland cancers 
Disease 
The KLK8 immunoreactivity was determined in normal 
salivary gland tissue and in malignant salivary gland 
tumors. In general, all the tumors showed a relatively 
high overall staining for both ductal and non-ductal 
cells, particularly mucoepidermoid carcinomas and 
adenocarcinoma NOS (Darling et al., 2008). 
Oral squamous cell carcinoma 
Disease 
Comparison of oral squamous carcinoma (OSC) cell 
lines with either overexpression or silencing of uPAR 
revealed that the more aggressive phenotype is 
associated with a co-overexpression of KLK5, KLK7, 
KLK8 and KLK10. Furthermore, 
immunohistochemical analysis demonstrated strong 
reactivity for KLKs 5, 7, 8 and 10 in both orthotopic 
murine tumors and human OSC tissues. These results 
suggest that KLK8 along with other KLKs is involved 
in malignant progression of oral squamous cell 
carcinoma (Pettus et al., 2009). 
Skin diseases 
Note 
KLK8 involvement in normal skin barrier formation 
and inflammatory skin disease pathology has recently 
become apparent. Work done in Klk8/neuropsin-null 
mice suggested that Klk8/neuropsin is involved in skin 
barrier homeostasis, whereby healing of chemically 
wounded or UV-irradiated mouse skin is largely 
impaired in its absence (Kitayoshi et al., 1999; Kirihara 
et al., 2003; Kishibe et al., 2012). Additionally, the 
dramatic increase of KLK8 mRNA in hyperkeratotic 
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skin of psoriasis vulgaris, seborrheic keratosis, lichen 
planus, and squamous cell carcinoma patients, 
compared with normal and basal cell carcinoma skin, 
suggested that human KLK8 is involved in keratinocyte 
differentiation and skin barrier formation (Kuwae et al., 
2002; Shingaki et al., 2010; Shingaki et al., 2012). 
KLK8 protein overexpression was also detected in 
psoriasis, atopic dermatitis, and peeling skin syndrome 
skin tissues (Komatsu et al., 2006; Komatsu et al., 
2007a; Komatsu et al., 2007b). KLK8 together with 
KLK5, KLK6, KLK7, KLK10 and KLK12 was 
upregulated in normal human keratinocytes following 
SP1 silencing. Moreover, thymic stromal 
lymphopoietin (TSLP), an epithelial-derived T(H)2-
promoting cytokine, was induced in Sp1-silenced 
keratinocytes because of elevated KLK activity. This 
observation suggests that KLKs may contribute to 
T(H)2 immune responses in the skin by inducing TSLP 
(Bin et al., 2011). 
Brain diseases 
Note 
Under non-pathological conditions, KLK8 protein is 
localized mainly to the neurons of the cerebral cortex 
and hippocampus. Immunohistochemistry for KLK8 
also demonstrated signals in cerebellum (The Human 
Protein Atlas). A variety of transcriptional controls 
through both physiological and nonphysiological 
activity, such as long-term potentiation, chemically 
induced plasticity, kindling epileptogenesis, and 
experimental encephalitis, have been shown to 
positively regulate Klk8 gene expression in mice 
(Momota et al., 1998; Komai et al., 2000; He et al.,
2001; Ishikawa et al., 2011). Increased anxiety like 
response was also observed in Klk8/neuropsin-deficient 
mice (Horii et al., 2008). Recently, Attwood et al. 
(Attwood et al., 2011) have shown that Klk8/neuropsin 
is involved in stress-related plasticity in the amygdala 
by the cleavage of EphB2 during stress and the 
reduction of EphB2-NMDA binding. So currently, 
accumulating evidence supports pivotal roles of Klk8 
in the early phase of synaptic plasticity, late 
associativity, and behavioral memory (Shiosaka and 
Ishikawa, 2011). Further studies are required to 
determine if KLK8 is involved in human brain 
diseases, however an overexpression of KLK8 has yet 
been observed in Alzheimer's disease hippocampus 
(Shimizu-Okabe et al., 2001). 
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